The latest update is out from BerGenBio ASA ( (BRRGF) ).
BerGenBio ASA announced the discontinuation of its BGBC016 study of bemcentinib in combination with standard care in first-line non-squamous Non-Small Cell Lung Cancer patients with an STK11 gene mutation. The decision follows a preliminary analysis indicating insufficient response rates to justify further funding within the current cash runway. The company is now exploring strategic alternatives, which may include a sale, merger, or other transactions, as it enters a new phase.
More about BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer. Based in Bergen, Norway, with a subsidiary in Oxford, UK, the company is listed on the Oslo Stock Exchange.
Average Trading Volume: 37,305
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $35.85M
See more insights into BRRGF stock on TipRanks’ Stock Analysis page.